Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study identified low iron stores, potentially linked to heavy menstrual periods, as a trigger for diffuse nonscarring alopecia in a 31-year-old woman, leading to a diagnosis of telogen effluvium, for which iron supplementation was prescribed.

This review discusses factors affecting hair aging, such as inflammation and UV exposure, and examines potential anti-aging benefits of antioxidants and nutraceuticals for hair, but reports no new clinical results.

In this study, women with androgenetic alopecia showed higher cholesterol levels and carotid artery thickness, suggesting a potential link between female AGA and cardiovascular disease.

This study found that using minoxidil 2% as a mesotherapy injection showed more significant improvement in treating androgenetic alopecia in female patients than topical application.

This review discusses insights into the role of lipase H in controlling hair form and texture, emphasizing genetic mutations linked to autosomal recessive woolly hair/hypotrichosis, and reports no new experimental results.

This review discusses clinical variations, laboratory testing, and treatments for female-pattern alopecia, including finasteride, but reports no new clinical findings; the authors emphasize managing stress and psychological impacts.

This study found that purified apple juice containing procyanidin B-2 promoted hair growth in both mouse models and human clinical trials for male pattern baldness.

This article provides guidelines for diagnosing and managing androgenetic alopecia, highlighting that medical treatments like finasteride and minoxidil can effectively halt and reverse the condition's progression in many cases.

This study found that a combination of curcumin and piperine demonstrated moderate antioxidant activity, negligible cytotoxicity, and significant potential for promoting hair regrowth in rat models of alopecia, suggesting it could be a safe and effective natural alternative for managing hair loss.

In this case report, a 31-year-old man with frontal hairline recession saw a marked improvement in hair density and scalp appearance after undergoing six mesotherapy sessions alongside twice-daily application of 5% minoxidil, attributed to the treatment protocol combining nutrients, bioactives, and topical minoxidil.

In this case report, a 45-year-old man with treatment-resistant androgenetic alopecia experienced hair regrowth during oral bicalutamide treatment but also suffered adverse effects leading to discontinuation, highlighting the need for further studies on the safety and role of androgen receptor blockade in hair loss.

This review highlights novel drug delivery systems for alopecia that enhance localization in the pilosebaceous unit, reduce systemic exposure, and support sustained drug release, with a focus on optimized follicular carriers ranging from 100-300 nm for improved drug residence compared to conventional methods.

This study found that patients with androgenetic alopecia had increased scalp microbial diversity and reduced Staphylococcus abundance, particularly in the frontal and vertex regions, suggesting this dysbiosis as a sensitive indicator of AGA.

This study concluded that 5% topical Minoxidil remains a first-line treatment for female androgenetic alopecia by increasing hair density and thickness, while low-dose oral Minoxidil and combination therapies may also be effective.

This study found that combining platelet-rich plasma with topical minoxidil improved hair density and patient satisfaction in androgenetic alopecia patients more than minoxidil alone, with no serious adverse events reported.

In this review, researchers discussed various novel drug delivery systems, including lipid nanocarriers and polymeric nanoparticles, that may enhance treatment for alopecia by improving drug localization in hair follicles and reducing systemic exposure, potentially offering better outcomes than conventional treatments.

This study found that patients with androgenetic alopecia showed distinct scalp bacterial imbalances compared to healthy individuals, which were associated with unhealthy lifestyles. These microbial changes might contribute to follicular inflammation, potentially accelerating hair loss in these patients.

This study systematically reviewed androgenetic alopecia's clinical features, mechanisms, and treatments, highlighting that current drugs have limitations but emerging therapies and personalized treatment strategies could enhance efficacy and outcomes.

This study found that adipose-derived stem cell exosome injections were more effective than minoxidil in improving hair density and diameter in patients with androgenetic alopecia, with high patient satisfaction and manageable side effects.

This study reported that patients with mild to detectable androgenetic alopecia showed subjective improvement and a favorable safety profile after receiving a polynucleotide-based intradermal gel, with only one case of mild injection-site erythema noted among 60 participants over three months.

This study found that certain trichoscopic features, including hair diameter diversity patterns, helped differentiate female androgenetic alopecia from telogen effluvium in women, suggesting their potential use in clinical diagnosis.

This study examined finasteride degradation under stress conditions, identifying three unique degradation products in acidic environments, providing insights into impurity profiling and quality control for finasteride formulations.

In this study, DOP treatment improved hair regrowth in androgenetic alopecia by altering local steroid metabolism and follicular morphology.

This study found that in men with androgenetic alopecia, elevated triglycerides were the only factor consistently associated with the condition, suggesting a potential link between AGA and lipid metabolism, although other hormonal, metabolic, and sleep factors were not significantly different after propensity score matching.

This study concluded that Growth Factor Concentrate was more effective than Platelet-Rich Plasma in enhancing hair growth and patient satisfaction for individuals with androgenic alopecia and telogen effluvium, while maintaining similar safety.

In this case report, a 36-year-old male with androgenetic alopecia showed clinically visible improvement in hair density after three monthly sessions of microneedling combined with exosome application, although the authors note that further studies are needed to verify these findings.

This Delphi consensus study provides expert insights into hair aging, aims to enhance diagnostic precision and management of age-related hair changes, and identifies possible new therapeutic targets.

This case report observed that a 23-year-old male with androgenic alopecia experienced significant improvement, including complete resolution of baldness, after nine months of treatment with the homeopathic medicine Lycopodium clavatum 200.

In this case-control study, researchers observed that women with female pattern hair loss exhibited significantly lower serum IGF-1 levels than controls, while IGFBP-3 levels showed no significant difference, suggesting a potential role for IGF-1 in the condition.

This study found that exosome therapy led to significantly better hair regrowth and patient satisfaction than platelet-rich plasma in men with androgenetic alopecia.